Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the pancreas~  * Metastatic disease~* Unidimensionally measurable disease outside of the pancreas~  * At least 1 lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan~* Must have received 1, and only 1, prior gemcitabine-containing regimen for metastatic disease unless disease has recurred within 6 months after treatment with neoadjuvant or adjuvant gemcitabine-containing therapy~* No brain metastases~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* WBC at least 3,000/mm\^3~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 9.0 g/dL (transfusion allowed)~* No bleeding diathesis or coagulopathy~Hepatic~* Bilirubin no greater than upper limit of normal (ULN)~* AST and ALT no greater than 1.5 times ULN~* INR no greater than ULN~* PTT no greater than ULN~Renal~* Creatinine no greater than 2.0 mg/dL~* No clinically significant renal impairment~* Urine protein:creatinine ratio ≥ 1.0~Cardiovascular~* No prior myocardial infarction~* No prior stroke~* No clinically significant cardiovascular disease~* No uncontrolled hypertension (i.e., blood pressure greater than 160/110 mm Hg on medication)~* No unstable angina~* No New York Heart Association class II-IV congestive heart failure~* No serious cardiac dysrhythmia requiring medication~* No peripheral vascular disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No history or evidence of CNS disease (e.g, primary brain tumor or seizures not controlled with standard medical therapy)~* No other medical condition that would preclude study participation~* No psychiatric condition that would preclude study participation~* No other prior or concurrent malignancy that would preclude study participation~* No significant traumatic injury within the past 28 days~* No serious, nonhealing wound, ulcer, or bone fracture~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent prophylactic granulocyte or platelet growth factors~Chemotherapy~* See Disease Characteristics~* More than 4 weeks since prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* At least 4 weeks since prior radiotherapy~Surgery~* More than 7 days since prior fine needle aspirations or core biopsies~* More than 28 days since prior surgery (except closed biopsy or access port placement)~* More than 28 days since prior open biopsy~* No concurrent surgery~Other~* More than 4 weeks since prior experimental drug study participation~* More than 4 weeks since prior investigational drugs~* No other concurrent experimental drug study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rhuMAB-VEGF (Type: EXPERIMENTAL): bevacizumab 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks until disease progression, unacceptable toxicity or patient preference.
- rhuMAB-VEGF and Docetaxel (Type: EXPERIMENTAL): rhuMAB-VEGF,bevacizumab: 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks docetaxel, Taxotere: 35 mg/m2 given intravenously over 1 hour on days 1, 8, and 15 of each 28 day cycle. Treatment continued until evidence of disease progression, unacceptable toxicity, or patient preference.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy